{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:34Z","timestamp":1760137894950,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In recent years, guidelines for the management of acute coronary syndromes (ACS) have placed more emphasis on identifying patients at high bleeding risk (HBR). We set out to investigate the prevalence of HBR patients according to the Academic Research Consortium for High Bleeding Risk (ARC\u2013HBR) criteria in hospitalized patients with suspected non-ST-segment elevation myocardial infarction (NSTEMI). Consecutive patients were retrospectively enrolled between January and June 2019 from the emergency department (ED) of a tertiary hospital. The discharge diagnosis and baseline data were manually collected using electronic patient records and database searches. Patients with non-cardiac diagnoses were excluded. Overall, 212 patients were included in the study. A total of 146 (68.9%) patients were diagnosed with NSTEMI (Type 1), 47 (22.2%) with unstable angina pectoris (UAP) and 19 (9.0%) with \u201cother.\u201d HBR was detected in 47.6% (n = 101) of all patients. Common criteria for HBR among ACS patients were age (40.4%), chronic kidney disease (33.7%), and the use of oral anticoagulation medicines (20.2%). In conclusion, nearly half of the patients hospitalized for ACS fulfilled HBR criteria. According to contemporary guidelines, the management of HBR patients differs from that of non-HBR patients, and thus, a more comprehensive screening for HBR may be considered in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm11051324","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:11:14Z","timestamp":1646079074000},"page":"1324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of High Bleeding Risk among Hospitalized Suspected NSTEMI Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-2362","authenticated-orcid":false,"given":"Henri","family":"Kesti","sequence":"first","affiliation":[{"name":"Heart Centre, Turku University Hospital and University of Turku, 20521 Turku, Finland"},{"name":"Emergency Department, Turku University Hospital, 20521 Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henna","family":"M\u00e4kinen","sequence":"additional","affiliation":[{"name":"Emergency Department, Turku University Hospital, 20521 Turku, Finland"},{"name":"Faculty of Medicine, University of Turku, 20014 Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalle","family":"Mattila","sequence":"additional","affiliation":[{"name":"Emergency Department, Turku University Hospital, 20521 Turku, Finland"},{"name":"Faculty of Medicine, University of Turku, 20014 Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-6814","authenticated-orcid":false,"given":"Samuli","family":"Jaakkola","sequence":"additional","affiliation":[{"name":"Heart Centre, Turku University Hospital and University of Turku, 20521 Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko","family":"Lintu","sequence":"additional","affiliation":[{"name":"Emergency Department, Turku University Hospital, 20521 Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Porela","sequence":"additional","affiliation":[{"name":"Heart Centre, Turku University Hospital and University of Turku, 20521 Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. Appropriateness of Including Bleeding as a Component of a Quadruple End Point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention","volume":"66","author":"Giustino","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jcin.2016.04.009","article-title":"Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry","volume":"9","author":"Baber","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_11","first-page":"804","article-title":"Trade-off Ofmyocardial Infarction vs. Bleeding Types Onmortality after Acute Coronary Syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Randomized Trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_12","first-page":"1034","article-title":"Three, Six, or Twelve Months of Dual Antiplatelet Therapy after Des Implantation in Patients with or without Acute Coronary Syndromes: An Individual Patient Data Pairwise and Network Meta-Analysis of Six Randomized Trials and 11 473 Patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.4244\/EIJ-D-21-00181","article-title":"Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition","volume":"17","author":"Gragnano","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and Validation of the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) Score: A Pooled Analysis of Individual-Patient Datasets from Clinical Trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of High Bleeding Risk Criteria and Definition as Proposed by the Academic Research Consortiumfor High Bleeding Risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e008307","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","article-title":"Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention","volume":"12","author":"Natsuaki","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients","volume":"75","author":"Cao","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Choi, S.Y., Kim, M.-H., Lee, K.-M., Ko, Y.-G., Yoon, C.-H., Jo, M.-K., and Yun, S.-C. (2021). Comparison of Performance between ARC-HBR Criteria and PRECISE-DAPT Score in Patients Undergoing Percutaneous Coronary Intervention. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122566"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4244\/EIJ-D-20-00345","article-title":"High Bleeding Risk and Clinical Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention: The PENDULUM Registry","volume":"16","author":"Nakamura","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) Criteria in Patients Undergoing Percutaneous Coronary Intervention and Comparison with Contemporary Bleeding Risk Scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus Ticagrelor or Prasugrel in Patients Aged 70 Years or Older with Non-ST-Elevation Acute Coronary Syndrome (POPular AGE): The Randomised, Open-Label, Non-Inferiority Trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of Ticagrelor, the First Reversible Oral P2Y12 Receptor Antagonist, with Clopidogrel in Patients with Acute Coronary Syndromes: Rationale, Design, and Baseline Characteristics of the PLATelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"157","author":"James","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gimbel, M.E., Tavenier, A.H., Bor, W., Hermanides, R.S., de Vrey, E., Heestermans, T., Gin, M.T.J., Waalewijn, R., Hofma, S., and den Hartog, F. (2020). Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103249"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ahj.2015.07.030","article-title":"Ticagrelor or Prasugrel versus Clopidogrel in Elderly Patients with an Acute Coronary Syndrome: Optimization of Antiplatelet Treatment in Patients 70 Years and Older\u2014Rationale and Design of the POPular AGE Study","volume":"170","author":"Qaderdan","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-Month versus 12-Month or Longer Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-Label, Non-Inferiority Trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor Monotherapy in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor Alone vs.Ticagrelor plus Aspirin Following Percutaneous Coronary Intervention in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","unstructured":"Watanabe, H. (2021, January 27\u201330). STOPDAPT-2 ACS: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome. Proceedings of the European Society of Cardiology Virtual Congress, London, UK."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:05Z","timestamp":1760135345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11051324"],"URL":"https:\/\/doi.org\/10.3390\/jcm11051324","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}